ELAVL1 and glomerulosclerosis: Nonetheless, our results together with the therapeutic effect of KH3 for glomerulosclerosis we reported before [17] suggest that inhibition of HuR with KH3 holds great promise as a therapeutic agent for slowing/preventing the progression of kidney disease including glomerular and tubular fibrosis.